{"name":"Kiniksa Pharmaceuticals","slug":"kiniksa","ticker":"KNSA","exchange":"NASDAQ","domain":"kiniksa.com","description":"Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.","hq":"Hamilton, Bermuda / Lexington, MA","founded":0,"employees":"366","ceo":"Sanj K. Patel","sector":"Autoimmune / Autoinflammatory","stockPrice":47.23,"stockChange":-1.71,"stockChangePercent":-3.49,"marketCap":"$3.6B","metrics":{"revenue":677564000,"revenueGrowth":65,"grossMargin":54.7,"rdSpend":96853000,"netIncome":59005000,"cash":414073984,"dividendYield":0,"peRatio":63,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Tirbanibulin patent cliff ($100M at risk)","drug":"Tirbanibulin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"KPL-404","genericName":"KPL-404","slug":"kpl-404","indication":"Other","status":"phase_2"},{"name":"KPL-914","genericName":"KPL-914","slug":"kpl-914","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"KPL-404","genericName":"KPL-404","slug":"kpl-404","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KPL-914","genericName":"KPL-914","slug":"kpl-914","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Kiniksa reported fourth quarter and full year 2022 financial results, with net loss of $43.6 million and $184.5 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2022-06-28","type":"deal","headline":"Kiniksa Pharmaceuticals Announces Collaboration with Pfizer to Develop and Commercialize Tirbanibulin for Actinic Keratosis","summary":"Kiniksa entered into a collaboration agreement with Pfizer to develop and commercialize tirbanibulin for actinic keratosis.","drugName":"","sentiment":"positive"},{"date":"2021-12-20","type":"regulatory","headline":"FDA Approves Tirbanibulin for the Treatment of Actinic Keratosis","summary":"The FDA approved tirbanibulin for the treatment of actinic keratosis, a common skin condition.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1zNFBXNU94WEhVdWlaamhiVFNlc09qMEJwWkV2SmlkVEUyYmlXUlY0T0Z5OUhXdy1wUTk1Y290Zk4wQ1ZObzdrRUptVmZJNzZUU09HNnVUc1VJOWlCbTJFN1dJa0QyYnV1U1dwNEp3?oc=5","date":"2026-04-04","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan","headline":"If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQcGhlWGxNMDJYdGhUMmduQndhWElNNG9XN2dRVDZRTFozSTVTT3dabGh3LVc2V0wzMXRuMzhnT1d2UHp2d0Q1QjEyZmFQOE5rX1RDX19xSU11bUFDRGh0S3JBcU9SYS15OVBsZVlvQzUxTW1WRFpDTDFWOFhPMHc4b1RxaENXaFhvaDQzM0xLNUhSZw?oc=5","date":"2026-02-26","type":"pipeline","source":"Investor's Business Daily","summary":"Drug Stocks Lead Eight Hot New Names Onto IBD 50 List, Big Cap 20 And More - Investor's Business Daily","headline":"Drug Stocks Lead Eight Hot New Names Onto IBD 50 List, Big Cap 20 And More - Investor's Business Daily","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPSkJGNzEwbGxhdmhyRWR1ZkRPNFVwNE1udU1zazd2Q3ZWdHhheGNyWE91Y3FVNXVXQmVmdUN5VlI1VE9LU0JDMl9pRk5lX1JJLXd6UnROT2NlOUU3blg2WnVCMUJrWkZYX3NoQWQzTkU1Y01QZE9ERllyUFJPeFlDZHlYR0c3eGkwTkV1N3pqa2phejB3dF9yaUFlMl9NUmRBYVNFSl9lbGpOOXNkeDkwVlRIaVJLdw?oc=5","date":"2026-02-22","type":"pipeline","source":"AD HOC NEWS","summary":"Kiniksa (KNSA): Quiet Chart, Loud Pipeline — Is Wall Street Missing This? - AD HOC NEWS","headline":"Kiniksa (KNSA): Quiet Chart, Loud Pipeline — Is Wall Street Missing This?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5peU90aHVUSVJBZllUZzJkWWZ6RGVHWElhakxuenhZcEFUOVFBdG1XNkc2Z1Y1bnQxU1kzU0F5RGZ1aExiS3BzeGc1dll6YVBlTjI4SDQ5U3JUeC1TYllVRWtQSmF5UG1iU2xyUUY3dm5ILWxlOEJGbmRWbUpudw?oc=5","date":"2025-07-01","type":"deal","source":"Investor's Business Daily","summary":"Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind - Investor's Business Daily","headline":"Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind - Invest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZW1WcTkwSlNvaXBCTXdzVFVyOV95Q1l1SEpJdDl5VndZWE4tVHBkOGxHclFYdDAwVUF6eVhBb1J2eDFYNEVGd1hhSThkZk1KWEVLX0htX2xoNHhMdkhuYzNPZ3VYSmo2Nmh1VWlZaE1pQmg0WEdUWFdqTXVKcFBvY01LZHFYb283Z0JJZ1FQN2dPSDNnbnhzZy1TUDQyU2FicEpvR2pNZ3Q?oc=5","date":"2025-06-16","type":"pipeline","source":"Seeking Alpha","summary":"Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha","headline":"Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOZkNhSjJwaE1zbnpUaEVYSnhEZ3pDSk5aaWVOM01DVUprQTRSN0wwdEw2bElLMFdxTkNIRXQ0LWZLRVNOdHE4dHVZV0poLXI3OEp6Q2tORlBDNDhNbk8ybzVpcnVUUUV4Zkg0QTNXelJyekNXc3NLOTlfZ2U2eTNCWnlBWkpCanRMSkZiaWxJWWh0SFRCZ2E4?oc=5","date":"2025-03-02","type":"deal","source":"Yahoo Finance","summary":"Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Yahoo Finance","headline":"Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPdlhncUlBQW5sS01qeG96TTRPdmdubFBMRG1SQnY1ZnZOQjFhMjFld19ibGpXYXI3OVZRNlRLM0Z3Tlo1U0ozY1hHdmtWaWc5RW9iLWY4aVV5WGh6YmFwLWpOUEVON1dZeC04UHdfcTNNWmVkNEV6ZXBKZmFETG1SRklaaGo?oc=5","date":"2025-02-26","type":"pipeline","source":"The Pharma Letter","summary":"Kiniksa slims focus to cardiovascular diseases - The Pharma Letter","headline":"Kiniksa slims focus to cardiovascular diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBjeW9zNndNU05OdnhQQVd3ZExEMUNSRlFOWXQ1Z19mUGhYQXUwMzlhdEQ1MGN0eXQ5ak1ndTVVUVZxbzBtb0tZR190alg1YXFs?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"Kiniksa Pharmaceuticals International, Plc - KNSA - Stock Price & News - The Motley Fool","headline":"Kiniksa Pharmaceuticals International, Plc - KNSA - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5xNTk3RGdVSlJuTU1vNld4R2lzNnAwYno3SmZWb3RsbEdLZWV3N3NRSURhTXJUbWZEWVA4djdEaEd5QVVwMXFEdG9jVmwtc05hZXpjdmpMMjNFTkF6?oc=5","date":"2021-03-18","type":"pipeline","source":"TradingView","summary":"KNSA Stock Price and Chart — NASDAQ:KNSA - TradingView","headline":"KNSA Stock Price and Chart — NASDAQ:KNSA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE1EU1VQOXd5a3RXdzI3RW9aNFl3QkNFRzBXaTBaZVFvcTFNZFpWeUhCLW0xSjJvUFdrT2NOR0xHcUh0aG9Ua0IxNA?oc=5","date":"2020-12-01","type":"deal","source":"StockInvest.us","summary":"Kiniksa Pharmaceuticals . Class A Stock Price Forecast. Should You Buy KNSA? - StockInvest.us","headline":"Kiniksa Pharmaceuticals . Class A Stock Price Forecast. Should You Buy KNSA?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE93eGduVFVyNV9uMUpzajc0ZVhLVzMyR1ZTNFlMcEZMSmdTX3Q2cGpnUVBMT19wS1pSX3Axb3IwbmxiU0Z6SE84TjZvM2E1cmJyZ3c?oc=5","date":"2020-06-23","type":"pipeline","source":"Yahoo Finance UK","summary":"Kiniksa Pharmaceuticals International, plc (KNSA) stock price, news, quote and history - Yahoo Finance UK","headline":"Kiniksa Pharmaceuticals International, plc (KNSA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNRHZyYzN4b1hJLVN6V0pqd0ViUUhRMWk3bWxLN3d0VnhxRG92UnFzaWE4eVRJSUFldktFWnB3Ykh5LTEzZ0JlVzdSQVU0MzhkMlVLS3BBdjJiX09QaTFxVHgzRllkc0RwVWVnanhGbzhteDlIMm5qLTBVUTJSeGFhZg?oc=5","date":"2020-04-29","type":"pipeline","source":"MarketBeat","summary":"Top Kiniksa Pharmaceuticals International (KNSA) Competitors 2026 - MarketBeat","headline":"Top Kiniksa Pharmaceuticals International (KNSA) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"Tirbanibulin","drugSlug":"tirbanibulin","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":100000000}],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Pfizer","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Autoinflammatory Diseases"],"financials":{"source":"sec_edgar","revenue":677564000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":677564000,"period":"2025-12-31"},{"value":423239000,"period":"2024-12-31"},{"value":423239000,"period":"2024-12-31"},{"value":270259000,"period":"2023-12-31"},{"value":270259000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":96853000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":59005000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":763633000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":47.23,"previousClose":48.94,"fiftyTwoWeekHigh":50.03,"fiftyTwoWeekLow":18.25,"fiftyTwoWeekRange":"18.255 - 50.03","fiftyDayAverage":45.49,"twoHundredDayAverage":38.61,"beta":0.06,"enterpriseValue":3341064448,"forwardPE":29.1,"priceToBook":6.35,"priceToSales":5.33,"enterpriseToRevenue":4.93,"enterpriseToEbitda":42.41,"pegRatio":0,"ebitda":78775000,"ebitdaMargin":11.6,"freeCashflow":97890128,"operatingCashflow":137984992,"totalDebt":9497000,"debtToEquity":1.7,"currentRatio":3.79,"returnOnAssets":7.2,"returnOnEquity":11.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":8,"targetMeanPrice":57.38,"targetHighPrice":68,"targetLowPrice":50,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.5,"institutionHeldPercent":103.9,"sharesOutstanding":45900637,"floatShares":39902484,"sharesShort":3767914,"shortRatio":5.29,"shortPercentOfFloat":4.9,"epsTrailing":0.75,"epsForward":1.62,"revenuePerShare":9.13,"bookValue":7.44,"officers":[{"age":56,"name":"Mr. Sanj K. Patel","title":"CEO & Chairman of the Board"},{"age":51,"name":"Mr. Mark A. Ragosa C.F.A.","title":"Senior VP & CFO"},{"age":45,"name":"Mr. Ross Michael Moat","title":"COO & Principal Operating Officer"},{"age":60,"name":"Dr. John F. Paolini FACC, M.D., Ph.D.","title":"Executive VP & Chief Medical Officer"},{"age":43,"name":"Mr. Eben  Tessari","title":"Chief Strategy Officer"},{"age":54,"name":"Mr. Michael R. Megna CPA","title":"Senior VP & Chief Accounting Officer"},{"age":null,"name":"Ms. Mei  Jang","title":"Senior VP & Chief Technical Officer"},{"age":null,"name":"Mr. Jonathan  Kirshenbaum","title":"Investor Relations Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.kiniksa.com","phone":"44 78 1431 9100"}}